{"id":"nebivolol-and-atenolol","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Dizziness"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"3-8","effect":"Dyspnea"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL434394","moleculeType":"Small molecule","molecularWeight":"405.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are beta-1 selective adrenergic antagonists that decrease cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Nebivolol has additional vasodilatory properties through nitric oxide release. These agents are used to manage hypertension and cardiovascular conditions by reducing sympathetic nervous system activity.","oneSentence":"Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:43.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Heart failure"},{"name":"Post-myocardial infarction management"}]},"trialDetails":[{"nctId":"NCT04513509","phase":"NA","title":"Rate Control in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2020-10-21","conditions":"Atrial Fibrillation, Rate Control, Cardiopulmonary Exercise Test","enrollment":13},{"nctId":"NCT05019027","phase":"PHASE4","title":"N-of-1 for Beta-Blockers in Cardiac Amyloidosis","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-01-31","conditions":"Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis","enrollment":20},{"nctId":"NCT05585125","phase":"PHASE4","title":"A Preliminary Study for INFORMED","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-02-07","conditions":"Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction","enrollment":20},{"nctId":"NCT03596385","phase":"PHASE4","title":"TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion\"","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2018-10-31","conditions":"Myocardial Infarction","enrollment":8505},{"nctId":"NCT04757584","phase":"PHASE4","title":"Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-01","conditions":"Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction","enrollment":9},{"nctId":"NCT04767061","phase":"PHASE4","title":"Impact of Beta-blockers on Physical Function in HFpEF","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-04-01","conditions":"Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction","enrollment":9},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01522950","phase":"PHASE2","title":"A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-05","conditions":"Hypertension","enrollment":76},{"nctId":"NCT02467400","phase":"EARLY_PHASE1","title":"Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-01","conditions":"Osteoporosis, Age-Related","enrollment":165},{"nctId":"NCT03245996","phase":"PHASE4","title":"The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker","status":"COMPLETED","sponsor":"Tartu University Hospital","startDate":"2015-06","conditions":"Aortic Blood Pressure","enrollment":27},{"nctId":"NCT01316952","phase":"","title":"Coreg and HSRs-Updated Analysis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Hypersensitivity","enrollment":1},{"nctId":"NCT01230892","phase":"PHASE4","title":"Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-02","conditions":"Atherosclerosis, Endothelial Function","enrollment":29},{"nctId":"NCT00295542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2000-03","conditions":"Hypertension","enrollment":3344},{"nctId":"NCT00145210","phase":"PHASE3","title":"Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2005-04","conditions":"Hypertension","enrollment":630},{"nctId":"NCT00200421","phase":"PHASE2","title":"A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2002-05","conditions":"Hypertension","enrollment":110},{"nctId":"NCT00158093","phase":"PHASE1","title":"A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2003-06","conditions":"Hypertension","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nebivolol and Atenolol","genericName":"Nebivolol and Atenolol","companyName":"Mylan Bertek Pharmaceuticals","companyId":"mylan-bertek-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels. Used for Hypertension, Angina pectoris, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}